A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis

BACKGROUND: Accumulation of toxic free cholesterol in hepatocytes may cause hepatic inflammation and fibrosis. Volixibat inhibits bile acid reuptake via the apical sodium bile acid transporter located on the luminal surface of the ileum. The resulting increase in bile acid synthesis from cholesterol...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmer, Melissa, Jennings, Lee, Silberg, Debra G., Bliss, Caleb, Martin, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857122/
https://www.ncbi.nlm.nih.gov/pubmed/29548345
http://dx.doi.org/10.1186/s40360-018-0200-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857122/
https://www.ncbi.nlm.nih.gov/pubmed/29548345
http://dx.doi.org/10.1186/s40360-018-0200-y

Ejemplares similares